XML 33 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
LOSS PER SHARE
3 Months Ended
Feb. 28, 2013
Earnings Per Share [Abstract]  
Earnings Per Share [Text Block]

NOTE 9. LOSS PER SHARE

 

Basic loss per share is computed on the basis of the weighted-average number of shares of the Company’s common stock outstanding during the period. Diluted loss per share is computed on the basis of the weighted-average number of shares of the Company’s common stock and all dilutive potentially issuable shares of the Company’s common stock outstanding during the year. Shares of the Company’s common stock issuable upon conversion of debt and preferred stock, or exercise of stock options and stock warrants have not been included in the loss per share for the three months ended February 28, 2013 or February 29, 2012, as they are anti-dilutive.

 

The potential shares of the Company’s common stock issuable upon exercise of options or warrants, or upon conversion of other convertible securities issued by the Company, as of February 28, 2013 and February 29, 2012, are as follows:

 

    2013     2012  
             
Warrants     8,846,030       10,331,030  
Stock options     21,093,947       18,168,947  
Series B Convertible Preferred Stock     18,147,368       38,965,636  
Series I Convertible Preferred Stock     -       2,293,600  
LJCI Debenture     5,760,694,429       1,899,722,934  
      5,808,781,774       1,969,482,147  

 

MultiCell does not currently have sufficient authorized shares of its common stock to meet the commitments entered into under the Debenture and the related LJCI Warrants. As further discussed in Note 3, upon the conversion of any portion of the remaining $54,516 principal amount of the Debenture, LJCI is required to simultaneously exercise and purchase that same percentage of the remaining 5,451,629 warrant shares equal to the percentage of the dollar amount of the Debenture being converted. The agreement limits LJCI’s investment to an aggregate common stock ownership that does not exceed 9.99% of the outstanding shares of common stock of the Company. Furthermore, MultiCell has the right to redeem that portion of the Debenture that the holder may elect to convert and also has the right to redeem the outstanding principal amount of the Debenture not yet converted by the holder into common stock, plus accrued and unpaid interest thereon.